Advanced Search
NIAID
>
Labs & Scientific Resources
>
Resources for Researchers
>
DMID Resources for Researchers
>
Phase I Clinical Trial Units for Therapeutics
Phase I Clinical Trial Units for Therapeutics
Eligibility Criteria
Assurances to Users
Application Process
Approval Process
User Requirements
Services for Researchers
Phase I Clinical Trial Units for Therapeutics
About
What services does this resource provide?
The Phase I Clinical Trial Units for Therapeutics will assess the safety of therapeutic products (excluding biologics) within the scope of viral (other than HIV), bacterial, parasitic, and fungal pathogens, including NIAID priority bio-defense pathogens and emerging and re-emerging infectious diseases.
Where are services provided?
Services are provided by:
DynPort Vaccine Company with a clinical site at the Quintiles Phase I Unit in Overland Park, Kansas.
Clinical Research Management with clinical sites at Johns Hopkins University in Baltimore and Case Western Reserve University in Cleveland, Ohio.
Access
What are the eligibility criteria?
What assurances are provided to users?
What is the application process?
How are requests prioritized and/or approved?
What requirements must users fulfill?
Contact Info
Elizabeth Hollomon
Project Officer
E-mail:
hollomone@niaid.nih.gov
Web Site Tools
E-mail this page
Print this page
Bookmark & share
Contact Info
Elizabeth Hollomon
Project Officer
E-mail:
hollomone@niaid.nih.gov
Last Updated July 14, 2008
Home
|
Help
|
Site Index
|
Accessibility
|
Privacy Policy
|
Disclaimer
|
Links & Policies
|
FOIA
|
Contact Us